Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Abdulraheem Yacoub, MD, discusses option for patients with myelodysplastic syndromes and red blood cell transfusion dependence.

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis ...

Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.

In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear ...

In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell ...